Edition:
United Kingdom

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

588.80INR
7:34am GMT
Change (% chg)

Rs-2.85 (-0.48%)
Prev Close
Rs591.65
Open
Rs591.50
Day's High
Rs598.15
Day's Low
Rs587.30
Volume
484,351
Avg. Vol
1,459,368
52-wk High
Rs663.40
52-wk Low
Rs480.20

Latest Key Developments (Source: Significant Developments)

Cipla Launches Q-Tib Globally
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Cipla Ltd ::SAYS CIPLA LAUNCHES Q-TIB GLOBALLY.SAYS GOT APPROVAL FOR PRODUCT Q-TIB FROM WORLD HEALTH ORGANISATION.Q-TIB WILL HELP PREVENT TUBERCULOSIS INFECTION IN PEOPLE LIVING WITH HIV.  Full Article

Cipla gets final approval for generic Dacogen​
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Cipla Ltd :Says ‍Cipla receives final approval for generic Dacogen​.Drug indicated for treatment of patients with myelodysplastic syndromes.Product is available for shipping immediately.  Full Article

Cipla gets final approval for generic Pulmicort Respules
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Cipla Ltd ::Cipla receives final approval for generic Pulmicort Respules.Drug indicated for maintenance treatment of asthma, as prophylactic therapy in children 12 months to 8 years of age.Product available for shipping immediately.  Full Article

India's Cipla Sept qtr consol profit up about 19 pct
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cipla Ltd :Sept quarter consol net profit 4.23 billion rupees versus profit of 3.54 billion rupees last year.Consensus forecast for sept quarter consol net profit was 4.20 billion rupees.Sept quarter consol net sales 39.88 billion rupees versus 36.72 billion rupees last year.  Full Article

Cipla says US unit gets USFDA final approval for generic Renvela tablets‍​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Cipla Ltd :Says us subsidiary receives final approval for generic Renvela tablets‍​.  Full Article

Cipla's U.S. unit gets final FDA nod for generic Renvela tablets
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Cipla Ltd ::Says co's U.S. unit gets final FDA nod for generic Renvela tablets ‍​.  Full Article

India's Cipla March-qtr loss narrows
Thursday, 25 May 2017 

May 25 (Reuters) - Cipla Ltd :Consol March quarter net loss 617.9 million rupees.Consol march quarter total income from operations 35.82 billion rupees.Recommended payment of dividend of 2 rupees per share.Consol net loss in March quarter last year was 928.3 million rupees as per Ind-AS; consol total income from operations was 33.15 billion rupees.  Full Article

Cipla gets EIR from USFDA for its Indore facility
Wednesday, 12 Oct 2016 

Cipla Ltd :Cipla receives EIR from the US FDA for its Indore facility.  Full Article

Cipla Ltd exec says co expects about 200 mln rupees of impact from FDC ban, NLEM in Q2
Friday, 12 Aug 2016 

Cipla Ltd : Cipla's Samina Vaziralli says "the family is completely committed", "absolutely no prospect" of selling the company . Exec says expects about 200 million rupees of impact from FDC ban and NLEM in Q2 . Further company coverage [CIPL.NS] ((Bangalore.newsroom@thomsonreuters.com)).  Full Article

Cipla Ltd appoints Umang Vohra as MD, global CEO
Friday, 12 Aug 2016 

Cipla Ltd : Accepted resignation of Subhanu Saxena as MD and global CEO wef August 31 . Appointed Umang Vohra as MD and global CEO .  Full Article

BRIEF-Cipla Launches Q-Tib Globally

* SAYS GOT APPROVAL FOR PRODUCT Q-TIB FROM WORLD HEALTH ORGANISATION